Thermo Fisher with Frontier Bio to develop novel HIV treatment

Thermo Fisher will be the exclusive drug substance manufacturing partner of 3BNC117 to support the pivotal study, process performance qualification (PPQ) and global commercial supply.

Thermo Fisher Scientific Inc., the world leader in serving science, announced collaboration with Frontier Biotechnologies Inc. to develop a novel treatment for human immunodeficiency virus (HIV). 

The product will be manufactured at Thermo Fisher's site in St. Louis, Missouri.

"The combination of our expanded clinical trials capabilities in Suzhou and collaboration with Frontier, demonstrate our ability to offer our customers solutions to complex drug development challenges at every stage of development, said Michel Lagarde, executive vice president and president of Thermo Fisher's Pharma Services business. "We are looking forward to helping our customers take their molecule from the lab to the market, further enabling them make the world healthier."

This collaboration will integrate Thermo Fisher's expertise and regulatory track record in biologics drug development and manufacturing, as well as the outstanding innovation capabilities of Frontier in HIV treatment to expedite the commercialization of 3BNC117, to improve treatment for patients with HIV.

Building on its commitment to deliver the highest quality medicines to patients around the world, Thermo Fisher and Frontier Biotechnologies, Inc., a biopharmaceutical company based in China, announced a strategic partnership to accelerate the commercialization of 3BNC117, a novel broad-spectrum HIV neutralizing antibody.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.